Hematology

Longitudinal data showed hydroxyurea adherence declined steadily among patients with sickle cell disease, particularly in older age groups and those with executive difficulties.

Targeting PELI1 in chronic myeloid leukaemia may overcome treatment resistance and eliminate leukaemia stem cells, offering a promising new therapeutic strategy.

TP53 multihit alterations show reduced impact in del(5q) myelodysplastic neoplasms, with improved survival and delayed progression to acute myeloid leukaemia.

CRISPR gene therapy shows improved haemoglobin levels and reduced vaso occlusive events in severe sickle cell disease in early phase study data.

A new conditioning regimen for sickle cell transplantation shows high survival, strong engraftment, and low graft versus host disease in adolescents and adults.

The PASS aplastic anaemia diagnostic tool accurately differentiates acquired disease from inherited syndromes, enabling rapid clinical decision making using routine data.

Rapid lymphocyte expansion after CAR-T therapy predicts better survival in lymphoma but increases toxicity risk, highlighting its role as a key biomarker.

Individuals with anaemia showed higher levels of key Alzheimer blood biomarkers at baseline, including phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP).